

























































































































Transthyretin (TTR) amyloid cardiomyopathy
(ATTR-AC) is caused either by single-point
mutations in the TTR gene (ATTRv-AC) or by
deposition of the wild-type protein (ATTRwt-
AC).1 Long been considered a rare disease,
ATTR-AC has been increasingly recognized in
recent years, particularly among the elderly,1
mostly due to the possibility of a non-invasive
diagnosis through bone scintigraphy.2
Recent trials have demonstrated that
treatment with medications that silence TTR
production or stabilize the TTR tetramer
may favourably alter the progression of
ATTR-AC.3,4 In particular, tafamidis, a com-
pound that inhibits TTR dissociation, has
demonstrated to improve the prognosis of
both ATTRv-AC and ATTRwt-AC patients
enrolled in the Transthyretin Amyloidosis
Cardiomyopathy Clinical Trial (ATTR-ACT).3
However, whether the sample enrolled in
the ATTR-ACT could be representative of
a real-world (RW) ATTR-AC population
remains unknown. To get some insight into
this question, we compared the main char-
acteristics of subjects treated with tafamidis
(n = 264) in ATTR-ACT,3 with those of a
large Italian cohort of ATTR-AC patients.
We included in the present analysis all
consecutive ATTR-AC patients diagnosed
according to international recommendations2
at five Italian referral centres between January
2010 and August 2018, regardless of their
clinical status at diagnosis and vital status
at follow-up. We excluded patients with
other form of amyloid cardiomyopathy, as
well as those ATTR-AC subjects enrolled in
the ATTR-ACT trial (29 patients enrolled
in Bologna, Florence and Pavia). ATTRv-AC
patients with a prevalent neurological phe-
notype were also excluded according to the
ATTR-ACT protocol.5 Participating centres
were requested to include main patients’
characteristics at first clinical evaluation in a
centralized anonymized database. All patients
had signed an informed consent for process-
ing of personal data for scientific research
purpose. Characteristics of the two samples
were compared using one-sample t-test or
Wilcoxon test, or test for proportion as
appropriate.
Our RW sample included 507 Caucasian
patients (Table 1). The distribution of ATTRv-
AC and ATTRwt-AC was comparable in
ATTR-ACT vs. RW patients, although 19
RW ones refused to undergo genetic testing.
Age was similar in the two groups, but RW
patients were less frequently males, and
had higher prevalence of hypertension and
diabetes. In addition, their clinical conditions
were significantly better, including higher
blood pressure and heart rate and a lower
New York Heart Association (NYHA) func-
tional class. Results of blood tests were
available for more than 50% of the RW sam-
ple, and showed lower natriuretic peptide
and troponin levels, and higher creatinine
clearance. At echocardiography, RW patients
displayed similar wall thickness, but larger left
atrial dimension and a greater left ventricular
ejection fraction than ATTR-ACT subjects.
They were also more likely to receive car-




In this RW sample enrolled over the past
8 years, ATTR-AC patients at diagnosis had
an apparently milder disease in terms of
NYHA functional class, haemodynamics and
biomarkers when compared to trial subjects.
Such a healthier RW clinical profile may be
the result of the greater awareness that
ATTR-AC has gained in the recent years6 and
of the widespread use of cardiac imaging tech-
niques allowing an earlier and non-invasive
© 2019 The Authors








































































































































































































































Table 1 Characteristics of transthyretin amyloid cardiomyopathy trial patients at enrolment versus real-world
patients at diagnosis
ATTR-ACT trial Real-world P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total population 264 (tafamidis pooled) 507 (Italian cohort)
Age (years) 74.5± 7.2 74.5± 8.7 0.988
Male sex 241 (91.3) 429 (84.6) <0.0001
Caucasian 211 (79.9) 507 (100) <0.0001
Co-morbidities
Hypertension 145 (54.9) 301 (59.4) 0.021
Diabetes 20 (7.6) 67 (13.2) <0.0001
TTR genotype
ATTRv 63 (23.9) 120 (23.7) 0.458
ATTRwt 201 (76.6) 368 (72.6) 0.070
Genetics not performed 0 (0) 19 (3.7)
Blood pressure (supine) (mmHg)
SPB 115.4±15.4 130.3±18.7 <0.0001
DPB 70.4±10.3 76.9±10.1 <0.0001
Heart rate (supine) (b.p.m.) 70.7±12.3 73.1±12.7 <0.0001
NYHA class
I 24 (9.1) 106 (20.9) <0.0001
II 162 (61.4) 287 (56.6) 0.026
III 78 (29.5) 112 (22.1) <0.001
IV 0 (0) 2 (0.4)
NT-proBNP (pg/mL) 2995.9 [1751.5–4861.5] 2547 [1333–4578] (n = 398)a <0.001
BNP (pg/mL) [if NT-proBNP not available] 285 [150–629] (n = 71)a
Creatinine clearance (mL/min) 58.8±17.9 66.5± 25.5 (n = 475)a <0.0001
Troponin I (ng/mL) 0.14 [0.09–0.20] 0.02 [0.01–0.07] (n = 294)a <0.0001
Troponin T (ng/L) [if troponin I not available] 54.5 (42.0–88.0) (n = 78)a
Echocardiography
LA diameter (mm) 43.8± 7 46.6± 6.5 <0.0001
IVS thickness (mm) 16.7± 3.8 16.9± 3.0 0.134
LVEF (%) 48.4±10.3 53.4±10.7 <0.0001
Medications
Diuretics 175 (66.3) 391 (77.1) <0.0001
Beta-blockers 76 (28.8) 233 (46.0) <0.0001
ACEi/ARBs 69 (26.1) 251 (49.5) <0.0001
Antithrombotics 105 (39.8) 199 (39.3) 0.818
Values are given as mean± standard deviation, number (%), or median [Q1–Q3].
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ATTR-ACT, Transthyretin Amyloidosis Cardiomyopathy Clinical Trial; ATTRv-AC, hered-
itary variant transthyretin amyloid cardiomyopathy; ATTRwt-AC, wild-type transthyretin amyloid cardiomyopathy; BNP, B-type natriuretic peptide; DBP, diastolic blood
pressure; IVS, interventricular septum; LA, left atrial; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart
Association; SBP, systolic blood pressure; TTR, transthyretin.
aNumber of patients with available data.
diagnosis of the disease.2 This could also
explain the higher proportion of NYHA class
I–II patients in our cohort, as already shown
in other series.7 Notably, these characteris-
tics resemble those of ATTR-ACT patients
that seemed to benefit the most from the
experimental treatment with tafamidis.3 On
the other hand, an ATTR-AC diagnosis may
increasingly be reached in individuals already
‘on-treatment’ for other cardiovascular con-
ditions, such as hypertension and diabetes,
which were more prevalent and probably led
to a wider usage of cardiac medications in
our RW population.
Tafamidis only inhibits further TTR amyloid
deposition, thus it is expected to have its
greater impact when administered early in
the disease course.3 Accordingly, its benefits
on hospitalization and survival were not
immediate, but seen after approximately 12
and 18months of treatment, respectively.3
Therefore, the possibility, as highlighted by
the present report, of diagnosing ATTR-
AC in patients mostly with few symptoms
may represent a striking opportunity in
order to offer tafamidis treatment to a
greater number of subjects expected to
benefit from it, altering significantly the
course of their disease. Medications that
silence TTR production have also shown
some preliminary positive results, but their
investigation so far has been limited to
ATTRv-AC patients of younger age and
with milder disease as compared to the
ATTR-ACT and RW ones analysed here.4
Interestingly, the pre-defined proportion
of ATTRv/ATTRwt-AC of ATTR-ACT was
replicated by chance in our RW population,
© 2019 The Authors




























































































































































in which ATTRv-AC was mostly related to
Ile68Leu, Val122Ile and Val30Met late-onset
mutations.
In the context of cardiovascular medicine,
it is very unusual to see a RW population
being clinically comparable to (or even
more fit than) a trial population; thus, we
did not anticipate these results. However,
some limitations should be acknowledged.
A shorter duration of the ATTR-AC disease
could explain the RW milder phenotype;
however, this information was neither
available from ATTR-ACT nor from our
database. In addition, our RW sample may
have suffered from substantial referral bias,
as ATTR-AC patients with a greater burden
of co-morbidities and a lower life expectancy
might less likely be referred to dedicated
centres for more advanced diagnostics and
treatments. Nonetheless, the RW population
included in this analysis might represent a
sizable indicator of patients suitable for a
dedicated specific treatment in our country.
Finally, we did not systematically collect
important parameters that were considered
as exclusion criteria in ATTR-ACT, namely a
low modified body mass index and a short
6-min walk test distance.3 These indicators
of poor prognosis should always be assessed
before considering a patient for expensive
therapies with survival benefits expected only
at long-term follow-up.
In conclusion, our findings that RW ATTR-
AC patients closely resemble those enrolled
in ATTR-ACT have relevant implications,
considering that ATTR-AC is still considered
a rare condition, and specific treatments will
likely become initially available for a small
proportion of the affected patients, primarily
because of the relevant costs.
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